Global Vasomotor Symptoms Market Insight, Epidemiology and Market Forecast Report 2017-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Vasomotor Symptoms – Market Insight, Epidemiology and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The Vasomotor symptoms epidemiology division provides insights about the historical and current patient pool of Hot flashes/Night sweats and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total diagnosed prevalent cases of vasomotor symptoms (Hot flashes/Night sweats) patients were found to be more in postmenopausal women aged 40 – 65 years in 7MM during the study period, i.e., 2017-2030. The International Menopause Society (IMS) Council of Affiliated Menopause Societies (CAMS) have collaborated in studies to compare the prevalence of HFs in different climates, continents, and at different altitudes.

The disease epidemiology covered in the report provides historical as well as forecasted vasomotor symptoms epidemiology segmented as the prevalence of Vasomotor symptoms, Prevalent Cases of Hot Flashes associated with Post Menopause, Severity-specific cases of Hot flashes (Mild, Moderate, and Severe) in post-menopause, and Diagnosed and Treatable Cases of Vasomotor symptoms. The report includes the prevalent scenario of Vasomotor symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise – Vasomotor symptoms (Hot flashes/Night sweats) Epidemiology

The epidemiology segment also provides the Vasomotor symptoms (Hot flashes/Night sweats) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent population of Vasomotor Symptoms Associated with post-menopause in 7MM countries was 41,096,968 in 2017. (Read more…)

Vasomotor symptoms (Hot flashes/Night sweats) Drug Chapters

The drug chapter segment of the Vasomotor symptoms (Hot flashes/Night sweats) report encloses the detailed analysis of Hot flashes marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Vasomotor symptoms (Hot flashes/Night sweats), clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Vasomotor symptoms (Hot flashes/Night sweats) Marketed Drugs

Bijuva: TherapeuticsMD

Bijuva (estradiol and progesterone) is a registered trademark of TherapeuticsMD and is a novel combination of 17?-estradiol and progesterone developed using SYMBODA technology. It is the first and only FDA-approved combination of bio-identical estradiol and bio-identical progesterone in a single daily oral capsule and indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause. It was approved in October 2018 and launched in April 2019.

Vasomotor symptoms (Hot flashes/Night sweats) Emerging Drugs

NT-814: KaNDy Therapeutics

NT-814 is a first in class, orally-administered, potent, and selective dual antagonist of both the neurokinin-1 and 3 receptors under development by KaNDy Therapeutics as a therapy for a range of Women’s Health conditions. It addresses VMS by modulating a group of estrogen-sensitive neurons in the hypothalamus in the brain called the kisspeptin-neurokinin B-dynorphin-KNDy neurons. NT-814 has successfully completed Phase IIa and IIb studies demonstrating the potential to reduce the frequency and severity of hot flashes and night sweats (called vasomotor symptoms) of the menopause. Now it is planning to progress to enter Phase III study in this anchor indication.

Key Topics Covered:

1. Key Insights

2. Vasomotor Symptoms (Hot Flashes/Night Sweats): Market Overview at a Glance

2.1. Total Market Share (%) Distribution of Vasomotor Symptoms (Hot Flashes/Night Sweats) in 2017

2.2. Total Market Share (%) Distribution of Vasomotor Symptoms (Hot Flashes/Night Sweats) in 2030

3. Executive summary

4. Organizations

5. Epidemiology and Market Methodology

6. Vasomotor Symptoms (VMS) associated with menopause: Disease Background and Overview

6.1. Introduction

6.2. Vasomotor Symptoms (Hot Flashes/Night Sweats)

6.3. Signs and Symptoms of VMS

6.4. Pathophysiology of VMS

6.5. Risk factors for VMS

6.6. Effects of VMS

6.7. Premature (early) Menopause

6.8. Menopause Associated with Breast Cancer Treatment

7. Epidemiology and Patient Population

7.1. Key Findings

8. Total Prevalent cases of Vasomotor Symptoms (Hot Flashes/Night Sweats) in Post-menopause in 7MM

9. Country Wise-Epidemiology of Hot Flashes Associated with Post-menopause

9.1. United States

9.1.1. Assumptions and Rationale

9.1.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in the United States

9.1.3. Severity-specific cases of Hot Flashes in Post-menopause in the United States

9.2. EU5 Countries

9.3. Germany

9.4. France

9.5. Italy

9.6. Spain

9.7. The United Kingdom

9.8. Japan

10. Treatment Algorithm, Current Treatment, and Medical Practices

10.1. Hormonal Therapies

10.1.1. Estrogen Replacement Therapies

10.1.2. Progestational Agents

10.2. Non-hormonal pharmacological treatments for vasomotor symptoms

10.2.1. Clonidine

10.2.2. Serotonin Reuptake Inhibitors

10.2.3. Gabapentin

10.2.4. Behavioral Modifications

10.3. Complementary alternative medicines (CAM)

11. Unmet Needs

12. Marketed drugs by class

12.1. Hormonal Therapies

12.1.1. Estrogen Only Therapies

12.1.2. Combination Therapies

12.2. Non-Hormonal Therapies

12.2.1. Approved Drug

12.2.2. Off-Label Antidepressants

12.3. Recent additions in Hormonal therapies

12.4. Bijuva: TherapeuticsMD

12.4.1. Drug Description

12.4.2. Regulatory Milestones

12.4.3. Other Development Activities

12.4.4. Clinical Development

12.4.5. Safety and Efficacy

12.4.6. Product Profile

13. Emerging Therapies

13.1. Key Cross Competition

13.2. Hormonal Based therapies

13.3. Donesta: Mithra Pharmaceuticals (Donesta Biosciences)

13.3.1. Product Description

13.3.2. Other Developmental Activities

13.3.3. Clinical Development

13.3.4. Safety and Efficacy

13.3.5. Product Profile

13.4. Non-Hormonal Based therapies

13.5. NT-814: KaNDy Therapeutics

13.6. FP-101: Fervent Pharmaceuticals

13.7. Fezolinetant: Astellas Pharma

13.9. SJX 653: Sojournix

13.10. MT-8554: Mitsubishi Tanabe Pharma

14. Hot Flashes: Seven Major Market Analysis

14.1. Key Findings

14.2. Market Size of Hot Flashes associated with Post Menopause in 7MM

15. Seven Major Market Outlook

16. Market Drivers

17. Market Barriers

18. SWOT

19. Case Studies

19.1. A Case Report of Hot Flashes for Menopause Awareness

19.2. A Case Report of a symptomatic patient in whom hormone therapy (HT) was abruptly stopped

20. KOL Views

21. Appendix

Companies Mentioned

• TherapeuticsMD
• Mithra Pharmaceuticals (Donesta Biosciences)
• KaNDy Therapeutics
• Fervent Pharmaceuticals
• Astellas Pharma
• Sojournix
• Mitsubishi Tanabe Pharma

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/t4osal

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900